
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune is a well-positioned company with several key candidates in late-stage development, including their lead candidate pemvidutide, which has a balanced dual-action approach targeting both glucagon and GLP-1 receptors. Based on recent updates, it appears that the company is progressing smoothly towards initiating their PERFORMA pivotal trial and completing enrollment for their RECLAIM trial, further de-risking their development pipeline. With a strong financial position and potential for significant market opportunity in both MASH and ALD, Altimmune presents a compelling investment opportunity with a positive outlook for their stock.
Bears say
Altimmune is facing significant competition in the anti-NASH and obesity therapeutic markets, which may impact its future market penetration and sales revenue. The company's current financials and projections suggest a need for additional fundraising, which could result in share dilution. The successful development and commercialization of pemvidutide is crucial for Altimmune, and any delays or failures in these processes could negatively impact the company's business and stock price.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares